A Phase 1, Open-label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects with Myelodysplastic Syndrome (MDS), AML, Lymphoma, and Multiple Myeloma